Skip to main content

Table 1 Comparison of clinical and laboratory features between severe and non-severe pediatric patients with COVID-19

From: Clinical, laboratory, and chest CT features of severe versus non-severe pediatric patients with COVID-19 infection among different age groups

  Total Severe Non severe P- value
N Mean (SD)/percentage N Mean (SD)/percentage N Mean (SD)/percentage
Age, year 53 9.58 (5.35) 25 8.33 (5.51) 28 10.69 (5.05) 0.12
Sex
Male 22 41.5% 9 36.0% 13 46.4% 0.44
Female 31 58.5% 16 64.0% 15 53.6%
Disease onset to hospital admission duration 53 3.0 (2.0–6.25) 25 4.0 (2.0–7.5) 28 3.0 (1.25–7.0) 0.38
Hospital duration 53 5.37 (4.22) 25 7.16 (5.09) 28 3.78 (2.39) 0.01
ICU duration 53 0.69 (2.46) 25 1.48 (3.45) 28 0.00 (0.00) 0.01
ICU admission
Yes 6 11.3% 6 24.0% 0 0.0% 0.01
No 47 88.7% 19 76.0% 28 100.0%
Fever
Yes 42 79.2% 19 76.0% 23 82.1% 0.58
No 11 20.8% 6 24.0% 5 17.9%
Dry cough
Yes 40 75.5% 21 84.0% 19 67.9% 0.17
No 13 24.5% 4 16.0% 9 32.1%
Nasal congestion
Yes 5 9.4% 3 8.0% 2 10.7% 0.74
No 48 90.6% 23 92.0% 25 89.3%
Poor feeding
Yes 2 28.6% 1 20.0% 1 50.0% 0.43
No 5 71.4% 4 80.0% 1 50.0%
Body pain
Yes 14 30.4% 4 20.0% 10 38.5% 0.18
No 32 69.6% 16 80.0% 16 61.6%
Nausea
Yes 12 26.1% 6 30.0% 6 23.1% 0.60
No 34 73.9% 14 70.0% 20 76.9%
Diarrhea
Yes 5 9.4% 4 16.0% 1 3.6% 0.12
No 48 90.6% 21 84.0% 27 96.4%
Vomiting
Yes 11 20.8% 5 20.0% 6 21.4% 0.90
No 42 79.2% 20 80.0% 22 78.6%
Abdominal pain
Yes 3 6.5% 2 10.0% 1 3.8% 0.40
No 43 93.5% 18 90.0% 25 96.2%
Distress
Yes 23 43.4% 23 92.0% 0 0.0% < 0.01
No 30 56.6% 2 8.0% 28 100.0%
Outcome
Dead 1 1.9% 1 4.0% 0 0.0% 0.28
Alive 52 98.1% 24 96.0% 28 100.0%
Leukocyte count, × 109/L 53 9232.08 (4755.19) 25 10,064.00 (4477.06) 28 8489.29 (4951.64) 0.10
Leukopenia (< 3.5 × 109/L)
Yes 3 5.7% 0 0.0% 3 10.7% 0.09
No 50 94.3% 25 100.0% 25 89.3%
Leukocytosis(> 11 × 109/L)
Yes 17 32.1% 11 44.0% 6 21.4% 0.08
No 36 67.9% 14 56.0% 22 78.6%
Lymphocyte, % 53 26.249 (13.17) 25 29.22 (15.61) 28 23.59 (10.11) 0.25
Lymphopenia (< 20%)
Yes 21 39.6% 8 32.0% 13 46.4% 0.28
No 32 60.4% 17 68.0% 15 53.6%
Lymphocytosis(> 40%)
Yes 7 13.2% 6 24.0% 1 3.6% 0.03
No 46 86.8% 19 76.0% 27 96.4%
CRP, mg/L 53 22.5 (5.0–82.75) 25 23.0 (3.5–81.0) 28 15.5 (4.25–60.25) 0.82
ESR, mm/h 16 20.0 (14.0–59.25) 5 19.0 (13.0–85.0) 11 21.0 (14.0–51.0) 0.86
O2 saturation, % 51 96.5 (94.0–97.75) 25 93.0 (86.5–95.0) 26 97.5 (95.0–98.0) < 0.01
Respiratory rate 52 32.48 (13.36) 25 37.88 (15.66) 27 27.48 (8.35) 0.01
Antiviral therapy
Yes 11 20.8% 4 16.0% 7 25.0% 0.42
No 42 79.2% 21 84.0% 21 75.0%
Antibacterial therapy
Yes 49 92.5% 23 92.0% 26 92.9% 0.91
No 4 7.5% 2 8.0% 2 7.1%
Comorbid disease
Comorbid disease
  Yes 20 37.7% 12 48.0% 8 28.6% 0.14
  No 33 62.3% 13 52.0% 20 71.4%
G6PD deficiency
Yes 4 7.5% 3 12.0% 1 3.6% 0.25
  No 49 92.5% 22 88.0% 27 96.4%
Cardiovascular
  Yes 3 5.7% 2 8.0% 1 3.6% 0.49
  No 50 94.3% 23 92.0% 27 96.4%
Gastrointestinal
  Yes 3 5.7% 2 8.0% 1 3.6% 0.49
  No 50 94.3% 23 92.0% 27 96.4%
Other comorbid diseases
  Yes 6 11.3% 2 8.0% 4 14.3% 0.47
  No 47 88.7% 23 92.0% 24 85.7%
  1. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. Continuous and categorical variables were analyzed using independent t-test/Mann-Whitney U test and χ2/Fisher’s exact tests, respectively. P-value less than 0.05 was considered as significant